Abstract
Approximately 1.67 million new cases of breast cancer (BC) are diagnosed annually, and patient survival significantly decreases when the disease metastasizes. The axillary lymph nodes (ALNs) are the main doorway for BC tumoral cell escape, through which cells can disseminate to distant organs. The immune response, which principally develops in the lymph nodes, is linked to cancer progression, and its efficacy at controlling tumoral growth is compromised during the disease. Immunohistochemistry (IHC) is one of the most widely used research techniques for studying the immune response. It allows the measurement of the expression of particular markers related to the immune populations. This review focuses on the role of the immune populations in the primary tumour in the locoregional metastasis of the ALN, and the relationship of the immune response in these regions to distant metastasis. We considered only studies of immune cells using IHC techniques. In particular, lymphocytes, macrophages and dendritic cells all play important roles in BC and have been extensively studied. Although further research is needed, there is much evidence of their role in the invasion of the ALN and distant organs. Their association with tumoral growth or protection has not yet been demonstrated decisively and is very likely to be determined by a combination of factors. Moreover, even though IHC is a widely used technique in cancer diagnosis and research, there is still room for improvement, since its quantification needs to be properly standardized.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ammar A, Mohammed RA, Salmi M, Pepper M, Paish EC, Ellis IO, Martin SG (2011) Lymphatic expression of CLEVER-1 in breast cancer and its relationship with lymph node metastasis. Anal Cell Pathol (Amst) 34:67–78. https://doi.org/10.3233/ACP-2011-0002
Aras S, Zaidi MR (2017) TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer 117:1583–1591. https://doi.org/10.1038/bjc.2017.356
Asano K, Nabeyama A, Miyake Y et al (2011) CD169-positive macrophages dominate antitumor immunity by cross-presenting dead cell-associated antigens. Immunity 34:85–95. https://doi.org/10.1016/j.immuni.2010.12.011
Baker M (2015) Reproducibility crisis: blame it on the antibodies. Nature 521:274–276. https://doi.org/10.1038/521274a
Baptista MZ, Sarian LO, Derchain SF, Pinto GA, Vassallo J (2016) Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol 47:78–84. https://doi.org/10.1016/j.humpath.2015.09.006
Bembenek A, Li J, Loddenkemper C, Kemmner W, Stein H, Wernecke KD, Schlag PM (2008) Presence of mature DC-lamp + dendritic cells in sentinel and non-sentinel lymph nodes of breast cancer patients. Eur J Surg Oncol 34:514–518. https://doi.org/10.1016/j.ejso.2007.05.013
Blenman KRM, He TF, Frankel PH et al (2018) Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. NPJ Breast Cancer 4:28. https://doi.org/10.1038/s41523-018-0081-7
Bogels M, Braster R, Nijland PG et al (2012) Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunology 1:798–809. https://doi.org/10.4161/onci.20427
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Buldakov M, Zavyalova M, Krakhmal N et al (2017) CD68 + , but not stabilin-1 + tumor associated macrophages in gaps of ductal tumor structures negatively correlate with the lymphatic metastasis in human breast cancer. Immunobiology 222:31–38. https://doi.org/10.1016/j.imbio.2015.09.011
Burugu S, Asleh-Aburaya K, Nielsen TO (2017) Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer 24:3–15. https://doi.org/10.1007/s12282-016-0698-z
Chang AY, Bhattacharya N, Mu J et al (2013) Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med 11:242. https://doi.org/10.1186/1479-5876-11-242
Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321–330. https://doi.org/10.1038/nature21349
Chen Z, Chen X, Zhou E et al (2014) Intratumoral CD8(+) cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One 9:e95475. https://doi.org/10.1371/journal.pone.0095475
Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA (2013) Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol 44:2055–2063. https://doi.org/10.1016/j.humpath.2013.03.010
Coffelt SB, Kersten K, Doornebal CW et al (2015) IL-17-producing gamma delta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522:345–348. https://doi.org/10.1038/nature14282
de la Cruz-Merino L, Barco-Sanchez A, Henao Carrasco F et al (2013) New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013:785317. https://doi.org/10.1155/2013/785317
de Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J, Holgado E (2017) Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice. Biochim Biophys Acta Rev Cancer 1868:527–537. https://doi.org/10.1016/j.bbcan.2017.10.003
Denkert C, Loibl S, Noske A et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113. https://doi.org/10.1200/JCO.2009.23.7370
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210
Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71:5601–5605. https://doi.org/10.1158/0008-5472.CAN-11-1316
Gadalla R, Hassan H, Ibrahim SA et al (2019) Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR1/SDF-1 axis. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05129-8
Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother 29:233–240. https://doi.org/10.1097/01.cji.0000199193.29048.56
Gardner A, Ruffell B (2016) Dendritic cells and cancer immunity. Trends Immunol 37:855–865. https://doi.org/10.1016/j.it.2016.09.006
Gingras I, Azim HA Jr, Ignatiadis M, Sotiriou C (2015) Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies. Clin Adv Hematol Oncol 13:372–382
Gokmen-Polar Y, Thorat MA, Sojitra P, Saxena R, Badve S (2013) FOXP3 expression and nodal metastasis of breast cancer. Cell Oncol (Dordr) 36:405–409. https://doi.org/10.1007/s13402-013-0147-3
Goto W, Kashiwagi S, Asano Y et al (2018) Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. ESMO Open 3:e000305. https://doi.org/10.1136/esmoopen-2017-000305
Gupta R, Babb JS, Singh B, Chiriboga L, Liebes L, Adams S, Demaria S (2011) The numbers of FoxP3 + lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest 29:419–425. https://doi.org/10.3109/07357907.2011.585193
Gu-Trantien C, Loi S, Garaud S et al (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123:2873–2892. https://doi.org/10.1172/JCI67428
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322. https://doi.org/10.1016/j.ccr.2012.02.022
Hansen M, Andersen MH (2017) The role of dendritic cells in cancer. Semin Immunopathol 39:307–316. https://doi.org/10.1007/s00281-016-0592-y
Heiskala M, Leidenius M, Joensuu K, Heikkila P (2018) High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer. Virchows Arch. https://doi.org/10.1007/s00428-018-2461-7
Hou Y, Nitta H, Wei L et al (2018) PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Breast J 24:911–919. https://doi.org/10.1111/tbj.13112
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2018) SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission. Accessed 8 Nov 2018
Jaraj SJ, Camparo P, Boyle H, Germain F, Nilsson B, Petersson F, Egevad L (2009) Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer. Virchows Arch 455:375–381. https://doi.org/10.1007/s00428-009-0833-8
Jubb AM, Soilleux EJ, Turley H et al (2010) Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol 176:2019–2028. https://doi.org/10.2353/ajpath.2010.090908
Kakavand H, Vilain RE, Wilmott JS et al (2015) Tumor PD-L1 expression, immune cell correlates and PD-1 + lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 28:1535–1544. https://doi.org/10.1038/modpathol.2015.110
Kalyuzhny AE (2009) The dark side of the immunohistochemical moon: industry. J Histochem Cytochem 57:1099–1101. https://doi.org/10.1369/jhc.2009.954867
Karahalli O, Acar T, Atahan MK, Acar N, Haciyanli M, Kamer KE (2017) Clinical and pathological factors affecting the sentinel lymph node metastasis in patients with breast cancer. Indian J Surg 79:418–422. https://doi.org/10.1007/s12262-016-1500-3
Kerjaschki D (2005) The crucial role of macrophages in lymphangiogenesis. J Clin Invest 115:2316–2319. https://doi.org/10.1172/JCI26354
Kim JM, Chen DS (2016) Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27:1492–1504. https://doi.org/10.1093/annonc/mdw217
Kim R, Emi M, Tanabe K, Arihiro K (2006) Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 7:1006–1016. https://doi.org/10.1016/S1470-2045(06)70975-5
Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP (2005) Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2:e284. https://doi.org/10.1371/journal.pmed.0020284
Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180–185. https://doi.org/10.1016/j.addr.2015.11.009
La Rocca G, Anzalone R, Corrao S et al (2008) CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. Histopathology 52:203–212. https://doi.org/10.1111/j.1365-2559.2007.02919.x
Li M, Li A, Zhou S, Xu Y, Xiao Y, Bi R, Yang W (2018) Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer 18:4. https://doi.org/10.1186/s12885-017-3916-y
Liu Y, Cao X (2016) Characteristics and significance of the pre-metastatic niche. Cancer Cell 30:668–681. https://doi.org/10.1016/j.ccell.2016.09.011
Loi S (2013) Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2:e24720. https://doi.org/10.4161/onci.24720
Loi S, Sirtaine N, Piette F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860–867. https://doi.org/10.1200/JCO.2011.41.0902
Lorusso G, Ruegg C (2012) New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 22:226–233. https://doi.org/10.1016/j.semcancer.2012.03.007
Maguire A, Brogi E (2016) Sentinel lymph nodes for breast carcinoma: a paradigm shift. Arch Pathol Lab Med 140:791–798. https://doi.org/10.5858/arpa.2015-0140-RA
Malter W, Hellmich M, Badian M, Kirn V, Mallmann P, Kramer S (2018) Factors predictive of sentinel lymph node involvement in primary breast cancer. Anticancer Res 38:3657–3662. https://doi.org/10.21873/anticanres.12642
Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH (2009) Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 9:231. https://doi.org/10.1186/1471-2407-9-231
Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M (2011) Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8 + T cells. Virchows Arch 459:391–398. https://doi.org/10.1007/s00428-011-1145-3
Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M (2012) The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. Virchows Arch 461:639–646. https://doi.org/10.1007/s00428-012-1338-4
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416. https://doi.org/10.1038/nrclinonc.2016.217
Matkowski R, Gisterek I, Halon A et al (2009) The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 29:2445–2451
Miettinen M (1990) Immunohistochemistry of solid tumors. Brief review of selected problems. APMIS 98:191–199
Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 27:16–25. https://doi.org/10.1016/j.coi.2014.01.004
Miyan M, Schmidt-Mende J, Kiessling R, Poschke I, de Boniface J (2016) Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J Transl Med 14:227. https://doi.org/10.1186/s12967-016-0983-9
Muenst S, Schaerli AR, Gao F et al (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 146:15–24. https://doi.org/10.1007/s10549-014-2988-5
Nakamura R, Sakakibara M, Nagashima T et al (2009) Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur J Cancer 45:2123–2131. https://doi.org/10.1016/j.ejca.2009.03.024
Nathanson SD, Shah R, Rosso K (2015) Sentinel lymph node metastases in cancer: causes, detection and their role in disease progression. Semin Cell Dev Biol 38:106–116. https://doi.org/10.1016/j.semcdb.2014.10.002
Nielsen SR, Schmid MC (2017) Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm 2017:9624760. https://doi.org/10.1155/2017/9624760
Nienhuis HH, Gaykema SB, Timmer-Bosscha H et al (2015) Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. Pharmacol Ther 147:63–79. https://doi.org/10.1016/j.pharmthera.2014.11.004
Ogiya R, Niikura N, Kumaki N et al (2016) Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci 107:1730–1735. https://doi.org/10.1111/cas.13101
Padera TP, Meijer EF, Munn LL (2016) The lymphatic system in disease processes and cancer progression. Annu Rev Biomed Eng 18:125–158. https://doi.org/10.1146/annurev-bioeng-112315-031200
Peng Y, Butt YM, Chen B, Zhang X, Tang P (2017) Update on immunohistochemical analysis in breast lesions. Arch Pathol Lab Med 141:1033–1051. https://doi.org/10.5858/arpa.2016-0482-RA
Pillai R, Kannan S, Chandran GJ (1993) The immunohistochemistry of solid tumours: potential problems for new laboratories. Natl Med J India 6:71–75
Pinder SE (2010) Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol 23(Suppl 2):S8–S13. https://doi.org/10.1038/modpathol.2010.40
Poindexter NJ, Sahin A, Hunt KK, Grimm EA (2004) Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 6:R408–R415. https://doi.org/10.1186/bcr808
Pruneri G, Vingiani A, Denkert C (2018) Tumor infiltrating lymphocytes in early breast cancer. Breast 37:207–214. https://doi.org/10.1016/j.breast.2017.03.010
Qin T, Zeng YD, Qin G et al (2015) High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget 6:33972–33981. https://doi.org/10.18632/oncotarget.5583
Ran S, Volk L, Hall K, Flister MJ (2010) Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17:229–251. https://doi.org/10.1016/j.pathophys.2009.11.003
Raschioni C, Bottai G, Sagona A et al (2018) CXCR73/CXCL12 signaling and protumor macrophages in primary tumors and sentinel lymph nodes are involved in luminal B breast cancer progression. Dis Markers 2018:5018671. https://doi.org/10.1155/2018/5018671
Schoppmann SF, Birner P, Stockl J et al (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161:947–956. https://doi.org/10.1016/S0002-9440(10)64255-1
Scully OJ, Bay BH, Yip G, Yu Y (2012) Breast cancer metastasis. Cancer Genomics Proteom 9:311–320
Shabo I, Stal O, Olsson H, Dore S, Svanvik J (2008) Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 123:780–786. https://doi.org/10.1002/ijc.23527
Shiota T, Miyasato Y, Ohnishi K et al (2016) The clinical significance of CD169-positive lymph node macrophage in patients with breast cancer. PLoS One 11:e0166680. https://doi.org/10.1371/journal.pone.0166680
Shou J, Zhang Z, Lai Y, Chen Z, Huang J (2016) Worse outcome in breast cancer with higher tumor-infiltrating FOXP3 + Tregs: a systematic review and meta-analysis. BMC Cancer 16:687. https://doi.org/10.1186/s12885-016-2732-0
Slodkowska J, Rojo MG (2011) Digital pathology in personalized cancer therapy. Folia Histochem Cytobiol 49:570–578
Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91:411–429. https://doi.org/10.1007/s00109-013-1021-5
Sobottka B, Pestalozzi B, Fink D, Moch H, Varga Z (2016) Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology 5:e1153208. https://doi.org/10.1080/2162402X.2016.1153208
Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86:1065–1073. https://doi.org/10.1189/jlb.0609385
Sompuram SR, Vani K, Tracey B, Kamstock DA, Bogen SA (2015) Standardizing immunohistochemistry: a new reference control for detecting staining problems. J Histochem Cytochem 63:681–690. https://doi.org/10.1369/0022155415588109
Song JL, Chen C, Yuan JP, Sun SR (2016) Progress in the clinical detection of heterogeneity in breast cancer. Cancer Med 5:3475–3488. https://doi.org/10.1002/cam4.943
Soysal SD, Tzankov A, Muenst SE (2015) Role of the tumor microenvironment in breast cancer. Pathobiology 82:142–152. https://doi.org/10.1159/000430499
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5:200ra116. https://doi.org/10.1126/scitranslmed.3006504
Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG (2014) Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14:159–172. https://doi.org/10.1038/nrc3677
Tatara T, Mukohara T, Shimono Y et al (2018) Expression of programmed death-1 in sentinel lymph nodes of breast cancer. J Surg Oncol 117:1131–1136. https://doi.org/10.1002/jso.24937
Torlakovic EE, Nielsen S, Vyberg M, Taylor CR (2015) Getting controls under control: the time is now for immunohistochemistry. J Clin Pathol 68:879–882. https://doi.org/10.1136/jclinpath-2014-202705
Treilleux I, Blay JY, Bendriss-Vermare N et al (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10:7466–7474. https://doi.org/10.1158/1078-0432.CCR-04-0684
Van Bockstal M, Floris G, Galant C, Lambein K, Libbrecht L (2018) A plea for appraisal and appreciation of immunohistochemistry in the assessment of prognostic and predictive markers in invasive breast cancer. Breast 37:52–55. https://doi.org/10.1016/j.breast.2017.10.012
Waisman A, Lukas D, Clausen BE, Yogev N (2017) Dendritic cells as gatekeepers of tolerance. Semin Immunopathol 39:153–163. https://doi.org/10.1007/s00281-016-0583-z
Walker RA (2006) Quantification of immunohistochemistry: issues concerning methods, utility and semiquantitative assessment I. Histopathology 49:406–410. https://doi.org/10.1111/j.1365-2559.2006.02514.x
Walker RA (2008) Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol 61:689–696. https://doi.org/10.1136/jcp.2006.041830
Yang J, Li X, Liu X, Liu Y (2015) The role of tumor-associated macrophages in breast carcinoma invasion and metastasis. Int J Clin Exp Pathol 8:6656–6664
Zhang C, Gao L, Cai Y et al (2016) Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. Biomaterials 84:1–12. https://doi.org/10.1016/j.biomaterials.2016.01.027
Zhang S, Zhang D, Yi S et al (2017) The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget 8:2863–2873. https://doi.org/10.18632/oncotarget.13752
Zhao YC, Ni XJ, Wang MH, Zha XM, Zhao Y, Wang S (2012) Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients. Med Oncol 29:2594–2600. https://doi.org/10.1007/s12032-012-0205-0
Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991–2001. https://doi.org/10.1172/JCI35180
Acknowledgements
This work was funded by projects PI11/0488 and PI13/02501 of the Institute of Health Carlos III, which is the main public research body that funds, manages and carries out biomedical research in Spain, and co-funded with European Union ERDF funds (European Regional Development Fund). It was also supported by the Project AIDPATH FP7-PEOPLE Project ID: 612471.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gibert-Ramos, A., López, C., Bosch, R. et al. Immune response profile of primary tumour, sentinel and non-sentinel axillary lymph nodes related to metastasis in breast cancer: an immunohistochemical point of view. Histochem Cell Biol 152, 177–193 (2019). https://doi.org/10.1007/s00418-019-01802-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00418-019-01802-7